DAVID WABWILE: Open Payments
NPI 1861162604 · DERRY, NH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$748 in 31 payments from 11 companies in 2025. Trend: 2023 $20 · 2024 $284 · 2025 $748
Food & beverage: $748
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $191 |
| Teva Pharmaceuticals USA, Inc. | 4 | $122 |
| Janssen Pharmaceuticals, Inc | 5 | $100 |
| Lundbeck LLC | 3 | $81 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $54 |
| Alkermes, Inc. | 2 | $47 |
| Collegium Pharmaceutical, Inc. | 2 | $46 |
| ABBVIE INC. | 2 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $26 |
Products named: ABILIFY MAINTENA, REXULTI, INVEGA SUSTENNA, UZEDY, ABILIFY ASIMTUFII, CAPLYTA, AUSTEDO XR, ARISTADA.
Industry payments across NH — which companies pay providers there.
